Celcuity Inc. Common Stock
CELCCelcuity Inc. (CELC) is a biotechnology company focused on developing personalized cancer therapies through its innovative molecular and cellular analysis platform. The company utilizes its proprietary diagnostic technology to identify specific patient subgroups, enabling targeted treatments and improving clinical outcomes. Celcuity aims to translate complex biological data into actionable insights for better cancer treatment strategies.
Company News
The article highlights three small-cap stocks that have shown impressive gains in 2025, including a biotech company, a fintech platform, and an online consignment store, each with unique market potential and growth trajectories.
Apis Capital Advisors invested $38.3 million in Celcuity, acquiring 776,000 shares during Q3 2025, making it their largest holding. Celcuity, a clinical-stage biotech firm, has seen its stock surge 669% in a year following positive phase 3 results for its cancer drug gedatolisib.
Celcuity announced promising Phase 3 trial results for gedatolisib, a multi-target PAM inhibitor for advanced breast cancer, demonstrating significant improvements in progression-free survival and response rates compared to standard treatment.
Several biotech companies are developing innovative cancer treatments, with promising clinical trial results in various cancer types, focusing on immunotherapy and personalized medicine approaches.
Celcuity (CELC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
